Prostate cancer and genetic contributions DOI Open Access
Wesley H. Chou, Cameron Chalker, Alexandra Sokolova

et al.

Andrology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 29, 2024

Abstract Prostate cancer remains a lethal disease for many men. Knowledge of genetic contributions to this condition has increasingly been used in its management. In narrative review, we summarize various alterations and syndromes associated with prostate cancer, including hereditary breast ovarian syndrome, Lynch among others. Indications germline testing are reviewed, as well incorporation data at different phases management such screening monitoring, treatment localized metastatic disease.

Language: Английский

PROTACs targeting androgen receptor signaling: Potential therapeutic agents for castration-resistant prostate cancer DOI Creative Commons
Yulu Zhang,

Annan Ming,

Junyan Wang

et al.

Pharmacological Research, Journal Year: 2024, Volume and Issue: 205, P. 107234 - 107234

Published: May 28, 2024

After the initial androgen deprivation therapy (ADT), part of prostate cancer may continuously deteriorate into castration-resistant (CRPC). The majority patients suffer from localized illness at primary diagnosis that could rapidly assault other organs. This disease stage is referred as metastatic (mCRPC). Surgery and radiation are still treatment CRPC, but have some adverse effects such urinary symptoms sexual dysfunction. Hormonal castration interfering receptor (AR) signaling pathway indispensable for most advanced patients, first- second-generation novel AR inhibitors effectively cure hormone sensitive (HSPC). However, resistance to these chemical agents inevitable many experience relapses. inhibitor mainly involves mutation, splice variant formation amplification, which indicates important role in CRPC. Proteolysis-targeting chimera (PROTAC), a potent technique degrade targeted protein, has recently undergone extensive development biological tool therapeutic drug. potential become next generation antitumor therapeutics it overcome shortcomings conventional small molecule inhibitors. In this review, we summarize molecular mechanisms on PROTACs targeting hoping provide insights drug clinical medication.

Language: Английский

Citations

8
Novel hormone therapies for advanced prostate cancer: understanding and countering drug resistance DOI Creative Commons
Zhipeng Wang, Jie Wang,

Dengxiong Li

et al.

Journal of Pharmaceutical Analysis, Journal Year: 2025, Volume and Issue: unknown, P. 101232 - 101232

Published: Feb. 1, 2025

Language: Английский

Citations

1
Advances in designing ternary complexes: Integrating in-silico and biochemical methods for PROTAC optimisation in target protein degradation DOI Creative Commons
Shareef Shaik,

Prasanna Kumar Reddy Gayam,

Manish Chaudhary

et al.

Bioorganic Chemistry, Journal Year: 2024, Volume and Issue: 153, P. 107868 - 107868

Published: Oct. 4, 2024

Language: Английский

Citations

4
Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches DOI Open Access
Adam Khorasanchi, Feng Hong, Yuanquan Yang

et al.

Cancer Drug Resistance, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 19, 2025

Metastatic castration-resistant prostate cancer (mCRPC) is driven by a complex network of resistance mechanisms against standard-of-care therapies, resulting in poor long-term outcomes. This review offers uniquely comprehensive and integrative perspective on these pathways, systematically examining both androgen receptor (AR)-dependent factors (including AR overexpression, point mutations, glucocorticoid signaling, splice variants, post-translational modifications, altered coregulators, intratumoral hormone biosynthesis) AR-independent pathways (such as neuroendocrine differentiation, lineage plasticity, alternative growth factor signaling). We also highlight influencing immunotherapy, chemotherapy, radiopharmaceutical therapy targeted therapy. By synthesizing emerging insights across domains, this not only clarifies the underlying biology mCRPC but identifies key leverage points for more effective interventions. Building foundation, we propose forward-looking framework overcoming drug resistance, emphasizing importance biomarker-guided patient selection, combination strategies that simultaneously target multiple mechanisms, novel therapies under investigation. These recommendations are intended to guide future clinical trial designs research priorities move beyond incremental improvements. Ultimately, synthesis aims serve resource clinicians researchers accelerate development durable, precision-based treatment mCRPC.

Language: Английский

Citations

0
Advancements in Proteolysis Targeting Chimeras for Targeted Therapeutic Strategies in Alzheimer’s Disease DOI Creative Commons

Qiuzhi Zhou,

Weixia Wang, Chunchu Deng

et al.

Molecular Neurobiology, Journal Year: 2025, Volume and Issue: unknown

Published: March 25, 2025

Language: Английский

Citations

0
Emerging frontiers in androgen receptor research for prostate Cancer: insights from the 2nd international androgen receptor Symposium DOI Creative Commons

Justus Simon Israel,

Laura-Maria Marcelin,

Christian Thomas

et al.

Journal of Experimental & Clinical Cancer Research, Journal Year: 2024, Volume and Issue: 43(1)

Published: July 17, 2024

Continued exploration of the androgen receptor (AR) is crucial, as it plays pivotal roles in diverse diseases such prostate cancer (PCa), serving a significant therapeutic focus. Therefore, Department Urology Dresden hosted an international meeting for scientists and clinical oncologists to discuss newest advances AR research. The 2nd International Androgen Receptor Symposium was held Dresden, Saxony, Germany, from 26-27.04.2024, organised by Dr. Holger H.H. Erb. Following format first meeting, more than 35 8 countries attended event recent developments, research challenges, identification venues An important new feature involvement PhD students young investigators, acknowledging high scientific quality their work. symposium included three covers: research, basic translational novel strategies target AR. Moreover, based on its increasing relevance, PSMA theranostic mini-symposium added at end allow audience theranostic. This report focuses highlights discussions meeting.

Language: Английский

Citations

2
Developmental Therapeutics in Metastatic Prostate Cancer: New Targets and New Strategies DOI Open Access
Jingsong Zhang, Juskaran Chadha

Cancers, Journal Year: 2024, Volume and Issue: 16(17), P. 3098 - 3098

Published: Sept. 6, 2024

There is an unmet need to develop new treatments for metastatic prostate cancer. With the development of targeted radioligand therapies, bispecific T cell engagers, antibody-drug conjugates and chimeric antigen receptor (CAR T) tumor-associated surface antigens have emerged as therapeutic targets in Ongoing completed clinical trials targeting prostate-specific membrane (PSMA), six transmembrane epithelial 1 (STEAP1), kallikrein-related peptidase 2 (KLK2), stem (PSCA), delta-like protein 3 (DLL3) cancer were reviewed. Strategies sequential or combinational therapy discussed.

Language: Английский

Citations

2
Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment DOI
Carly D. Miller, Pornlada Likasitwatanakul, Eamon Toye

et al.

Expert Review of Anticancer Therapy, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 14, 2024

Prostate cancer continues to be a major cause of morbidity and mortality for men worldwide. Enzalutamide, second-generation non-steroidal antiandrogen that blocks androgen receptor (AR) transcriptional activity, is treatment biochemically-recurrent, metastatic, castration sensitive, resistant tumors. Unfortunately, most patients ultimately develop resistance enzalutamide, making long-term with this agent challenging.

Language: Английский

Citations

2
FLT3-PROTACs for combating AML resistance: Analytical overview on chimeric agents developed, challenges, and future perspectives DOI
Heba M. Hesham, Eman M.E. Dokla, Eman Z. Elrazaz

et al.

European Journal of Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 277, P. 116717 - 116717

Published: Aug. 1, 2024

Language: Английский

Citations

1
Formulation Development, Evaluation and Profound Biological Activity of Polyherbal Gel containing Vigna radiate, <i>Aloe barbidenis</i> and <i>Moringa oleifera</i> DOI
Muhammad Tajammal Khan,

Simranjeet,

Sofia Pasi

et al.

International Journal of Newgen Research in Pharmacy & Healthcare, Journal Year: 2024, Volume and Issue: unknown, P. 142 - 148

Published: Dec. 31, 2024

This drug delivery system is designed to deliver a therapeutic amount of medicine the right place in body, allowing for rapid achievement and maintenance desired concentrations. Gels are solids or semisolids that include at least two substances; typically, they composed dense mass surrounded permeated by liquid. A number chemical components present, including organic acids, flavonoids, phenolic acids. Because its anti-inflammatory, antibacterial, antioxidant characteristics, Vigna radiata an effective acne treatment. Cosmetically ubiquitous Aloe barbadensis (Aloe Vera) has long been known efficacy alleviating skin conditions pigmentation, acne, burns, more. anti-inflammatory wound-healing it useful ingredient prescription treatments. In fact, there wide spectrum medicines available treatment from conventional antibiotics more contemporary methods even natural cures. Mixing gel with ethanolic extracts Moringa oleifera resulted improved carbopol base; this trio herbal may help reduce acne. The antimicrobial inquiry did not find any signs microbial contamination zone inhibition. vivo irritation examination detect lesions such defatting, unpleasant reactions, local systemic alteration.

Language: Английский

Citations

0